C12N 2501/22
Colony stimulating factors
Official title: Colony stimulating factors (G-CSF, GM-CSF)
C12N2501/22 (Colony stimulating factors) appears on 519 US grants and 945 published applications in this corpus.
Search patents in C12N- Granted patents
- 519
- Published applications
- 945
- Assignees
- 523
- Inventors
- 1,814
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 20 | 0 |
| 1998 | 24 | 0 |
| 1999 | 18 | 0 |
| 2000 | 18 | 0 |
| 2001 | 17 | 12 |
| 2002 | 9 | 34 |
| 2003 | 18 | 22 |
| 2004 | 10 | 46 |
| 2005 | 11 | 35 |
| 2006 | 9 | 30 |
| 2007 | 8 | 23 |
| 2008 | 11 | 25 |
| 2009 | 12 | 32 |
| 2010 | 17 | 31 |
| 2011 | 8 | 33 |
| 2012 | 19 | 26 |
| 2013 | 20 | 26 |
| 2014 | 21 | 21 |
| 2015 | 15 | 35 |
| 2016 | 25 | 35 |
| 2017 | 13 | 31 |
| 2018 | 28 | 44 |
| 2019 | 12 | 41 |
| 2020 | 17 | 39 |
| 2021 | 22 | 55 |
| 2022 | 17 | 63 |
| 2023 | 21 | 51 |
| 2024 | 29 | 62 |
| 2025 | 23 | 48 |
| 2026 | 15 | 45 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof11 Aug 2026US 12,702,681 B2Shanghai RoyalTech Med CO., Ltd
- CRISPR compositions and methods for promoting gene editing of ribosomal protein S19 (RPS19) gene4 Aug 2026US 12,698,513 B2EmendoBio Inc.
- Biocompatible conditioned cell medium compositions and uses thereof16 Jun 2026US 12,655,384 B2Cellum Biomedical, Inc.
- Neutrophil progenitors and related methods and uses9 Jun 2026US 12,650,428 B2Agency for Science, Technology and Research
- Composition for inducing dendritic cell differentiation, comprising metal-organic framework, and use thereof8 Oct 2026US 2026/0308523 A1Mediark Inc.
- Patrolling monocyte cellular therapy1 Oct 2026US 2026/0297525 A1New York Blood Center, Inc.
- SIRPalpha Knockout iPSC-derived and CAR-comprising Macrophages with Enhanced Anti-tumor Activity24 Sep 2026US 2026/0284104 A1Wisconsin Alumni Research Foundation
- Patient specific induced pluripotent stem cell derived macrophages for cell based therapy24 Sep 2026US 2026/0284107 A1Board of Regents, The University of Texas System
- Generation of induced neutrophils with increased activation and transmigration capabilities10 Sep 2026US 2026/0265695 A1
Most cited
By later US patents
- Method for improving autologous transplantation264US 5,199,942 AImmunex Corporation · 1993
- Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells210US 5,437,994 AThe Regents of the University of Michigan · 1995
- Methods and device for culturing human hematopoietic cells and their precursors206US 5,635,387 ACellPro, Inc. · 1997
- Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells159US 6,326,198 B1The Regents of the University of Michigan · 2001
- Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells151US 5,763,266 AThe Regents of the University of Michigan · 1998